Please assess the completion status of the following clinical trial:

Trial Title: Study of Aripiprazole in the Treatment of Children and Adolescents With Autistic Disorder (AD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Meets current Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) diagnostic criteria for AD and demonstrates serious behavioral problems; diagnosis confirmed by Autism, Diagnostic Interview-Revised (ADI-R).~* CGI score \> = 4 AND an ABC Irritability/Agitation subscale score \> = 18 at screening and baseline (randomization)~* Mental age of at least 18 months~* Male or female 6 to 17 years of age inclusive, at the time of randomization~Exclusion Criteria:~* Patients considered treatment resistant to neuroleptic medication based on lack of therapeutic response to 2 different neuroleptics after treatment of at least 3 weeks each~* Patients previously treated and not responding to aripiprazole treatment~* The patient is currently diagnosed with another disorder on the autism spectrum, including PDD-NOS, Asperger's Disorder, Rett's Disorder, Fragile-X Syndrome or Childhood Disintegrative Disorder~* Current diagnosis of bipolar disorder, psychosis, schizophrenia, or major depression~* A seizure in the past year~* History of severe head trauma or stroke~* Non-pharmacologic therapy (e.g., psychotherapy, behavior modification) should be stable prior to screening and consistent throughout the study

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- A1 (Type: EXPERIMENTAL): 5 mg
- A2 (Type: EXPERIMENTAL): 10 mg
- A3 (Type: EXPERIMENTAL): 15 mg
- B1 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).